Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With: MIS-C

  • Double Trouble: Vaccines Lag, Virulent Mpox Clade 1 Spreads

    The Centers for Disease Control and Prevention has released two health advisory alerts only a week apart, one dealing with the “urgent need” to vaccinate people for seasonal respiratory viruses; the second warning that a virulent type of mpox (monkeypox) virus is spreading in Africa.

  • Uncommon Diagnoses that Cannot Be Missed: An Update

    There are a variety of uncommon pediatric conditions that, if not detected, may result in devastating consequences. The authors review and update the current standard of care for a variety of conditions, including necrotizing fasciitis, DRESS syndrome, Kawasaki disease, MIS-C, Lemierre's, and RPA.

  • Researchers Use Advanced Technology to Detect MIS-C

    Scientists want to improve diagnostic techniques for multisystem inflammatory syndrome in children, which became a confounding problem during the COVID-19 pandemic.

  • Challenges in Diagnosing MIS-C

    Even though there are clear diagnostic criteria for multisystem inflammatory syndrome in children (MIS-C), the initial diagnosis is not always certain, and there can be overlapping concurrent bacterial, viral, and parasitic infections that also require prompt treatment.

  • Vaccinate Children Against MIS-C, a Serious Post-COVID Syndrome

    COVID-19 vaccination can greatly reduce multisystem inflammatory syndrome in children, a rare but serious complication associated with SARS-CoV-2 infection, researchers are finding.

  • Identifying and Managing MIS-C

    Pediatric SARS-CoV-2 infections are mild compared to adult infections. However, MIS-C, which typically develops four to six weeks after the initial infection, may be severe and characterized by mul­tiorgan dysfunction resulting from hyperinflammation. This article includes critical information regarding MISC-C recognition and management.

  • COVID-19 Vaccination Prevents Systemic Inflammatory Syndrome (MIS-C)

    The estimated effectiveness of two doses of Pfizer-BioNTech vaccine in the prevention of multisystem inflammatory syndrome in children was 91%.

  • MIS-C: Steroids and/or IVIG?

    Multisystem inflammatory syndrome in children (MIS-C) can be a devastating post-COVID-19 complication, but treatment seems effective. High-dose steroids and intravenous immune globulin (IVIG) are commonly used, although new studies give conflicting findings as to whether it is best to use both treatments together.
  • SARS-CoV-2 Antibodies and Multisystem Inflammatory Syndrome in Children

    SARS-CoV-2-related multisystem inflammatory syndrome in children (MIS-C) can be severe and life-threatening. New data suggest that the degree of elevation of spike protein receptor-binding domain antibodies could serve as a diagnostic marker of MIS-C as well as point to potential pathogenic processes.

  • Novel COVID-19 Syndrome in Adults

    Healthcare workers could be at risk of multisystem inflammatory syndrome linked to COVID-19, as the poorly understood condition, first seen in children, now is emerging in adults.